Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT01624038
Other study ID # huoepio
Secondary ID
Status Not yet recruiting
Phase Phase 2/Phase 3
First received April 13, 2012
Last updated June 18, 2012
Start date June 2012
Est. completion date December 2012

Study information

Verified date June 2012
Source Ain Shams University
Contact Amira A M Adly, Asst. prof.
Phone 0105245837
Email amiradiabetes@yahoo.com
Is FDA regulated No
Health authority Egypt: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The study hypothesis that treatment with Erythropoietin (EPO) combined with Human Erythropoietin (HUO) therapy will result in hematologic improvement in thalassemia intermedia patients.

Second is to determine whether any of the following correlate with improved hematologic response:

A decrease in hemolysis, as assayed by a decrease in LDH, compared to baseline levels,baseline Erythropoietin levels,baseline hemoglobin levels and baseline reticulocyte counts (or % circulating nucleated erythroblasts/100 WBCs).

Goal:

The aim is to assess the possibility of steady increase of hemoglobin levels in thalassemia intermedia patients by at least 1g/dl above baseline levels during therapy using Hydroxyurea and Erythropoietin, growth evaluation,quality of life (QoL) and decline transfusion requirements during study period. Also to report and compare adverse events with other published data regarding.


Description:

To determine whether any of the following correlate with improved hematologic response:

A decrease in hemolysis, as assayed by a decrease in LDH, compared to baseline levels,baseline Erythropoietin levels,baseline hemoglobin level and baseline reticulocyte counts (or % circulating nucleated erythroblasts/100 WBCs).

To assess the possibility of steady increase of hemoglobin levels in thalassemia intermedia patients by at least 1g/dl above baseline levels during therapy using Hydroxyurea and Erythropoietin, growth evaluation , quality of life ( QoL ) and decline transfusion requirements during study period. Also to report and compare adverse events with other published data regarding.

THE following criteria are used when including the patient in the study:

Patients with thalassemia intermedia.Diagnosis based on genetic mutations, hemoglobin electrophoresis and characteristic clinical data at presentation. Patients requiring different transfusion requirements and not transfusion dependent.Patients having a baseline hemoglobin of less than or equal to 6-8g/dl.Patients with normal renal and liver function.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Both
Age group 3 Years to 18 Years
Eligibility Inclusion Criteria:

- Patients with thalassemia intermedia. Diagnosis based on genetic mutations, hemoglobin electrophoresis and characteristic clinical data at presentation.

- Require different transfusion requirements and not transfusion dependent.

- Have a baseline hemoglobin of less than or equal to 6-8g/dl.

- Patients with normal renal and liver function.

Exclusion Criteria:

- Evidence of active hepatitis (ALT > 5 times above ULN).

- Evidence of renal impairment (serum creatinine > ULN).

- Patients who are dependent on red blood cell transfusions.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Hydroxyurea ,Epiao
Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week.
hydroxyurea, blood transfusion
Hydroxyurea was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/µL or a platelet count of less than 100,000/µL, in which case the drug was discontinued.

Locations

Country Name City State
Egypt hematology clinic ,pediatrics hospital, Ain Shams University hospital Cairo

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in baseline transfusion frequency with increase of pre-transfusion hemoglobin Decrease in baseline transfusion frequency with increase of pre-transfusion hemoglobin by calculation of transfusion index and mean hemoglobin level baseline and 6 month hemoglobin level and transfusion frequency Yes
Secondary Change in baseline quality of life assessment. Quality of life assessment using (QOL questionaire) at the begining and at 6 month baseline and 6 month QOL questionaire Yes
See also
  Status Clinical Trial Phase
Recruiting NCT06137079 - "Iron Overload and Endocrinological Diseases"
Completed NCT01224496 - Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders Phase 1/Phase 2
Completed NCT01496963 - Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia
Completed NCT01140321 - Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI Phase 2
Recruiting NCT05444894 - EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) Phase 1/Phase 2